Zydus Lifesciences Limited has informed the Exchange about press release dated 30-Aug-2022 titled Zydus announces Phase IV DREAM-CKD trial to generate Real World Evidence of Desidustat in patients with Chronic Kidney Disease induced anemia
Press Release Aug 30 2022
Filed with NSE · · 4 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced the commencement of a Phase IV clinical trial for Desidustat in patients with Chronic Kidney Disease induced anemia. The trial aims to generate Real World Evidence regarding the safety and efficacy of Desidustat over a period of time. This multicentre study will enroll a significant number of CKD patients in India, including both dialysis dependent and independent individuals. The press release emphasizes the importance of Real World Data in understanding the drug's effectiveness in diverse clinical settings.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Aug 11 2022
- Press Release Aug 05 2022
- Press Release Aug 04 2022
- Press Release Jul 26 2022
- Press Release Jul 21 2022
Later from Zydus Lifesciences
- Press Release Aug 31 2022
- Press Release Sep 07 2022
- Press Release Sep 09 2022
- Press Release Sep 12 2022
- Press Release Sep 13 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences